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AbstrACt
Introduction Adults with chronic obstructive pulmonary 
disease (COPD) and chronic heart failure (CHF) 
commonly suffer from exertional dyspnoea and fatigue. 
Exercise training is recommended in the management 
of both diseases, yet many of the outcome measures 
traditionally reported are disease specific and may not 
fully acknowledge the multimorbid older adult. Based on 
our previous research, a breathlessness rehabilitation 
programme for patients with COPD/CHF or combined 
disease has been introduced as a service improvement 
within University Hospital Leicester National Health Service 
Trust and has amalgamated aspects of cardiac and 
pulmonary rehabilitation. This has created an opportunity 
to expand the outcome measures assessed and introduce 
a holistic approach in a population that share common 
symptoms. Therefore, this multisite trial will explore the 
feasibility of collecting novel outcome markers as part 
of a comprehensive assessment prior to enrolment in a 
breathlessness rehabilitation programme for participants 
with COPD and/or CHF.
Methods and analysis The rehabilitation programme 
consists of 12 sessions, twice weekly, over a 6-week 
period. In addition to usual rehabilitation outcome 
measures, the trial will collect measures of future 
cardiometabolic risk including arterial stiffness, body 
composition, physical activity/sedentary time, frailty 
and symptom burden in a comprehensive rehabilitation 
assessment. The primary outcome measures will centre 
around feasibility (eg, acceptability of the comprehensive 
rehabilitation assessment, intervention delivery and the 
experiences and attitudes of healthcare professionals 
and participants). Focus groups and interviews will be 
conducted to further explore barriers and facilitators 
to the operation and participation in a breathlessness 
rehabilitation programme and the trial. Thematic analysis 
will be used for the interpretation of all qualitative data.
Ethics and dissemination The research ethics 
committee East Midlands Leicester-Central has provided 
ethical approval for the conduct of this trial. The results 
of the trial will be disseminated through appropriate 
conference proceedings and peer-reviewed journals.
trial registration number ISRCTN11636308
IntroduCtIon
Individuals with chronic obstructive 
pulmonary disease (COPD) and chronic 
heart failure (CHF) commonly suffer from 
exertional dyspnoea and the conditions often 
coexist.1 The prevalence of COPD in the CHF 
population has been suggested to range from 
9% to 52% in European and North American 
populations2 and estimates of the prevalence 
of CHF in the COPD population are around 
17%–20.5%.3 4 
Exercise training is recommended in 
the management of both diseases and 
forms an integral component of cardiac 
(CR) and pulmonary rehabilitation 
(PR) programmes.1 5 6 PR is a symptom-based 
multidisciplinary programme of exercise 
training, education and behavioural change.7 
Hospital days per patient8 and healthcare util-
isation9 have been shown to be reduced with 
PR. Commonly reported outcome measures 
strengths and limitations of this study
 ► The use of a mixed-methods approach in this trial 
is novel and will allow a breadth of information to 
be collected.
 ► This trial is assessing a novel breathlessness reha-
bilitation programme, managed by a National Health 
Service  trust. Therefore, the findings from this trial 
will be generalisable to routine clinical care.
 ► There is no comparison group or control data as 
rehabilitation is a National Institute for Health and 
Care Excellence recommendation for both chronic 
obstructive pulmonary disease and chronic heart 
failure.
 ► Spirometry is conducted in all study participants 
alongside a baseline measure of B-type natriuretic 
peptide, however, a repeat echocardiogram on all 
participants was beyond the scope of this study.
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for PR include quality of life, maximal and functional 
exercise capacity as reported by the Cochrane Systematic 
Review on PR for COPD10 and the 2017 National COPD 
PR audit in England and Wales; the latter also reported 
measures of dyspnoea and muscle strength.11 Indicators 
of cardiovascular risk were not reported, despite cardio-
vascular disease being a leading cause of death in those 
with mild to moderate COPD.12
CR is also a complex intervention and consists of 
health education and exercise training.13 The 2017 UK 
National CR Audit reported change in self-report phys-
ical activity, smoking status, body mass index, mood state, 
quality of life, maximal and functional exercise capacity 
and additional cardiovascular risk factors in all those that 
completed CR.14 CR has been shown to reduce the risk 
of overall and CHF-specific hospitalisation compared 
with usual care.15 Clinically important improvements in 
quality of life after exercise-based rehabilitation have been 
reported in a CHF population.15 Despite this, just 5.2% 
of patients who started CR in England, Wales, Northern 
Ireland, Isle of Man and the Channel Islands in 2017 had 
a diagnosis of CHF.14 The disability associated with CHF 
is more similar to COPD as opposed to a postmyocardial 
infarction population.16 The symptom-based model of PR 
including an individualised exercise prescription may be 
more appropriate for patients with CHF.17 
The model of PR was successfully expanded to include 
adults with CHF, and in a randomised controlled trial of 
either PR or usual care (no rehabilitation) those under-
going PR made improvements in exercise capacity and 
quality of life.18 In the same trial, adults with CHF exer-
cised alongside adults with COPD and the improvements 
in exercise capacity (assessed by the Incremental Shuttle 
Walk Test (ISWT)19 and Endurance Shuttle Walk Test 
(ESWT))20 were similar across groups, regardless of diag-
nosis. This trial was the first to suggest the model of PR is 
suitable for adults with CHF, to apply a ‘symptom-based’ 
approach to rehabilitation, and to show that both groups 
of patients could be trained together. Of note, partici-
pants in this study had either COPD or CHF and those 
with both pathologies were excluded.
Creating a rehabilitation programme in which relevant 
and appropriate outcome measures are assessed in adults 
who present with similar symptoms, regardless of their 
primary disease, appears to be a suitable advancement 
within cardiopulmonary-rehabilitation.21 Additionally, 
there is growing recognition of the multimorbid patient22 
and historically, this has not been assessed in either CR 
or PR, where the outcome measures assessed are largely 
disease specific. The establishment of a comprehensive 
rehabilitation assessment that incorporates measures 
from traditional CR and PR, as well as holistic measures 
of frailty and cardiometabolic risk will further our 
knowledge of symptom-based rehabilitation to ensure a 
patient-centred approach, recognising the burden and 
multimorbidity. At present, the feasibility of combining 
these outcome measures within breathlessness rehabilita-
tion is unknown.
Thus, the primary objective of the COpd and HEart 
failure REhabilitation trial (COHERE trial) will be to 
assess the feasibility of a breathlessness rehabilitation 
programme, including the collection of additional 
outcome measures, the delivery of the intervention and 
recruitment rates. The acceptability of the breathless-
ness rehabilitation programme and COHERE trial will be 
explored through the experiences and views of partici-
pants and healthcare professionals.
MEthods And AnAlysIs
trial design and registration
This is a multisite feasibility trial, assessing novel 
outcome measures within a breathlessness rehabilita-
tion programme for participants with a diagnosis of 
COPD and/or CHF. The rehabilitation programme is 
managed by University Hospitals of Leicester National 
Health Service Trust (UHL). Data will be collected at the 
Biomedical Research Centre Respiratory, Leicester, UK as 
well as the centres delivering rehabilitation. This trial will 
be conducted, analysed and reported according to the 
Consolidation Standards of Reporting Trials statement 
for feasibility trials.23
This trial has been registered on the ISRCTN website 
and UHL will act as study sponsor.
Patient and public involvement
The trial design was shared with patients enrolled in the 
breathlessness rehabilitation programme, prior to the 
trial commencing. Results will be disseminated to current 
and former PR and CR patients or interested members of 
the public within the local PR and CR patient and public 
involvement advisory group.
Participants
Eligibility criteria for patients
Patients eligible for inclusion in the trial will be: aged 
between 40 and 85 years, have a clinically confirmed diag-
nosis of COPD/CHF or combined disease, with a Medical 
Research Council (MRC) dyspnoea score 2 and above and 
will be referred to breathlessness rehabilitation as part of 
their standard care. COPD will be confirmed as part of 
the trial process through spirometry. Patients with CHF 
will be referred through the hospital or community heart 
failure service, where an echocardiogram is routinely 
conducted. A baseline value of B-type natriuretic peptide 
(BNP) will be measured in all participants.
Eligibility criteria for healthcare professionals
All healthcare professionals actively involved in the 
breathlessness rehabilitation programme will be invited 
to take part in a focus group.
setting
The current sites for the UHL and Leicestershire Part-
nership Trust breathlessness rehabilitation programme 
are Glenfield Hospital, Groby Road, Leicester, UK and 
Library. Protected by copyright.
 o
n
 20 August 2019 at Loughborough University/The Pilkington
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029387 on 16 July 2019. Downloaded from 
3Jones AV, et al. BMJ Open 2019;9:e029387. doi:10.1136/bmjopen-2019-029387
Open access
the National Centre for Sports and Exercise Medicine, 
Loughborough University, Loughborough, UK.
Procedure
Once a referral has been received by the rehabilitation 
team, eligible individuals will receive an invitation letter, 
reply slip and a detailed participant information sheet. 
This information will be given in person or sent by post. 
For those that decline the trial, reasons for this (if offered 
freely) may be taken as field notes or by an interview if 
participants consent to this. Interested participants will 
then be contacted and if appropriate, a research visit will 
be arranged. Once written informed consent has been 
provided, the participant’s involvement in the trial and 
any relevant results will be shared with their general prac-
titioner. Data from their usual care rehabilitation assess-
ment will be recorded. Where possible, the research visits 
will occur at least 10 days prior to and on completion of 
the rehabilitation programme. Participants will be asked 
to attend the visits after an overnight fast. On completion 
of the rehabilitation programme, participants repeat the 
research visit and usual rehabilitation assessment. Volun-
tary interviews or focus groups will then occur.
Intervention: breathlessness rehabilitation programme
The breathlessness rehabilitation programme is led by 
experienced physiotherapists, nurses and healthcare 
professionals. The programme consists of 12 supervised 
classes (typically twice a week for 6 weeks), with each 
class consisting of exercise training and education. The 
exercises consist of a combination of traditional CR and 
PR activities. Participants are led through a progressive 
warm-up, before completing individually prescribed 
aerobic and strength exercises. The aerobic components 
include walking (floor or treadmill) and stationary cycle 
ergometers. The ISWT19 is used to predict peak oxygen 
consumption (VO2) and walking speed is prescribed at 
80%–85% peak VO2.
20 The Borg Scale of Perceived Exer-
tion24 and the Modified Borg Breathlessness Scale25 are 
used to progress the exercise prescription. The strength 
component consists of sit-to-stand exercises (weighted 
if appropriate), bicep curls, upright rows and step ups. 
Participants are encouraged to complete 10 repetitions 
of each strength exercise 3 times per class. Participants 
are then led through a supervised cool-down before the 
educational component of the class. The educational 
topics covered within the breathlessness rehabilitation 
programme are presented in table 1. Outside of the super-
vised classes, participants are encouraged to complete a 
timed walk every day and strength training once a week at 
home/unsupervised.
Acceptability
The acceptability of the COHERE trial and the breath-
lessness rehabilitation programme will be assessed by the 
following, although not limited to:
A. Participants’ experience of the COHERE trial will be 
explored in qualitative interviews and focus groups.
B. Participants’ experience of the breathlessness reha-
bilitation programme will be explored in qualitative 
interviews and focus groups.
C. Proportion of participants who attended the follow-up 
research visit and reasons why participants did not 
complete the trial will be explored in qualitative in-
terviews.
D. The experience of healthcare professionals regarding 
the breathlessness rehabilitation programme, such as 
their confidence in working with varied cardiorespira-
tory patients, the content/structure of the breathless-
ness rehabilitation programme and the combining of 
CR and PR staff.
E. The views of healthcare professionals regarding the 
COHERE trial, such as the collection of addition-
al outcome measures and coordination of the pro-
gramme with the trial.
Feasibility
Measures for assessing feasibility are provided in table 2 
and will include the comprehensive rehabilitation assess-
ment, intervention delivery and recruitment.
data collection
Data will be collected following standard operating proce-
dures and will occur during specific research visits and 
usual care rehabilitation appointments. The timing of 
baseline and follow-up data collection cannot be stan-
dardised due to variation in the timing of participant’s 
starting and completing rehabilitation. Recruitment will 
occur from May 2018 to June 2020, with data collection 
ongoing until August 2020.
sample characteristics
Body composition
At both research visits, height, weight and waist circum-
ference will be measured to the nearest 0.1 cm, 0.1 kg 
and 0.1 cm, respectively. Waist circumference will be 
measured twice, unless the difference between the first 
two measurements is >3 cm, in which case a third measure-
ment will be taken. Bioelectrical Impedance Analysis will 
Table 1 Educational topics covered within breathlessness 
rehabilitation programme
All participants Benefits of exercise
Managing breathlessness
Relaxation techniques
Healthy eating
Energy conservation
Goal setting
Managing anxiety
Question and answers/signposting
Groups divided by 
primary diagnosis
Medications
Disease education
Managing exacerbations/symptom 
control
Chest clearance/frequently asked 
questions 
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be performed using a dual sensor scale (Tanita MC-780 
MA P; Tanita, Tokyo, Japan).
Physical function
The following three assessments are usual care and will be 
completed by healthcare professionals:
1. Maximal exercise capacity will be assessed using the 
ISWT.19
2. Endurance exercise capacity will be assessed using the 
ESWT,20 in which a participant aims to walk at 85% of 
their maximal ISWT walking speed.
3. Quadriceps strength will be assessed using an isomet-
ric maximum voluntary contraction . Participants will 
identify their dominant leg and where possible, three 
attempts will be made.
Frailty
Frailty is a clinical syndrome that is highly prevalent in 
old age26 and focuses on a holistic approach as opposed 
to organ-specific diagnoses.27 It has been suggested that 
25% of adults with COPD who are referred to PR28 are 
frail and it is highly prevalent in those with CHF.29 The 
Short Physical Performance Battery30 will be measured 
which comprises a series of three brief assessments; a 
standing balance test, a gait speed test and repeated sit-to-
stand tests.
Cardiometabolic health
Venous blood samples will be analysed for triglycerides, 
total cholesterol, low-density lipoproteins, high-density 
lipoproteins, glycated haemoglobin, plasma glucose, 
fibrinogen, high-sensitivity C reactive protein and BNP. 
BNP will only be analysed at the baseline research visit. 
All samples assessing cardiometabolic health will be taken 
in a fasted state.
Arterial stiffness will be assessed, specifically pulse wave 
velocity and pulse wave analysis using the Vicorder (Smart 
Medical, Gloucestershire, UK), according to manufac-
turer’s instructions. Participants will rest in the supine 
position for 5 min, before any measurements are taken. 
The air temperature in the room will be set at 21°C and 
the participants will lie on a bed set to 30°C with a pillow 
supporting them.
Respiratory health
Lung function will be assessed by forced spirometry using 
a Vitalograph Pneumotrac 6800 (Vitalograph, Buck-
ingham, UK) according to international guidelines.31 The 
device will be calibrated daily, and the pass/fail criteria is 
±3.0% of a fixed 3 L volume. The absolute and relative 
contraindications will be examined for each participant.32 
Participants will wear a nose clip during each attempt.
Symptoms and psychosocial health
Questionnaires will be used to assess the presence 
and severity of participants’ symptoms. The Hospital 
Anxiety and Depression Scale,33 the Dartmouth Coop-
erative Functional Assessment Charts (COOP) ,34 the 
COPD Assessment Test35 and the MRC breathlessness 
score36 are collected in routine care. The latter two ques-
tionnaires are only routinely collected in those with a 
Table 2 Feasibility of assessment and outcome measures
Indicators Data sources
Comprehensive rehabilitation assessment
  Completeness of additional outcome measures Case report forms
  Acceptability Interviews and focus groups with participants and healthcare 
professionals
Intervention delivery and process evaluation
  Completeness of usual care outcome measures Rehabilitation records
  Number of rehabilitation classes completed Rehabilitation records
  Number of participants that drop-out from rehabilitation 
programme
Rehabilitation records
  The experience of healthcare professionals regarding 
breathlessness rehabilitation and the COpd and HEart failure 
REhabilitation (COHERE) trial
Interviews and focus groups with healthcare professionals
  The experience of participants regards breathlessness 
rehabilitation and the COHERE trial
Interviews and focus groups with participants
  The training and resources needed to deliver the intervention Interviews and focus groups with healthcare professionals
Recruitment
  Feasibility of screening and recruiting participants Trial records and field notes
  Number of eligible participants, number of participants invited 
to participate in trial, number of participants that consent to 
trial
Medical records and trial records
  Number of participants that decline or drop-out of trial Trial records
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primary diagnosis of COPD, yet for research purposes, 
the MRC will be collected in all research participants. 
The Multidimensional Dyspnoea Profile (MDP)37 and 
the Dyspnoea-1238 will be used to assess breathlessness; 
the time frame for the MDP will state ‘the last 2 weeks’. 
Fatigue will be assessed using the Patient-Reported 
Outcomes Measurement Information System (PROMIS) 
Fatigue 7a Short Form39 and health-related quality of life 
will be assessed using the EQ-5D-5L.40 The Chronic Heart 
Questionnaire Self Report41 will be given to all partici-
pants to assess dyspnoea, fatigue and emotional function. 
Where possible, participants will independently complete 
the questionnaires. Efforts will be made to ensure all 
questionnaires are completed for research participants. 
The protocol has largely been developed to explore 
symptom-based and non-disease-specific questionnaires 
due to the population being recruited.
Objectively measured physical activity and time spent sedentary
Participants will be asked to wear a triaxial accelerometer 
(ActiGraph wGT3X-BT) using an adjustable waist belt 
with the monitor positioned over the right hip (midcla-
vicular line) for eight consecutive days preceding and 
again on completion of rehabilitation. This will measure 
time spent sedentary and in physical activity (ie, light, 
moderate and vigorous intensity) using cut-points, such 
as those published by Freedson et al42 and step count. 
Participants will be asked to wear the device during all 
waking hours but to remove it for water-based activities 
and during sleep. The accelerometer will also be given to 
participants to wear during their usual care assessments 
and during each rehabilitation class.
Self-reported physical activity
The clinical visit Pro-Active Questionnaire will be used,43 
in which participants recall physical activity over the last 
seven days using a 35-item questionnaire. This is a hybrid 
tool containing self-report information and two variables 
derived from the accelerometer.
sample size estimation and recruitment target
As this is a feasibility trial, a formal sample size calcu-
lation is not required; however, the aim is to consent a 
minimum of 40 participants with a representative mix 
of COPD, CHF and combined disease. The information 
gathered from this trial will be used to guide a sample size 
calculation for future studies. Posters raising awareness of 
the trial and the breathlessness rehabilitation programme 
will be placed within clinic rooms, the exercise rehabilita-
tion departments and online through UHL staff intranet. 
Efforts will also be made to raise awareness of the trial 
and the breathlessness rehabilitation programme with 
clinicians and healthcare professionals whom regularly 
refer patients.
Quantitative data analyses
As this is a feasibility trial, it is not appropriate to test 
for statistical differences over time or between groups. 
Therefore, quantitative data will be largely descriptive. 
Independent t-tests or analysis of variance (ANOVA) 
may be used to examine between-group differences and 
paired sample t-tests or repeated measures ANOVA may 
be used to examine within-group differences. Categorical 
data may be analysed using a X2or Fisher’s exact test. Data 
will be entered and stored on a secure web-based system, 
Research Electronic Data Capture as well as local pass-
word-protected computer files and drives. Analyses will 
be performed using SPSS V.23.0 (IBM Corp).
Participants will be provided with a unique identifica-
tion number, ensuring their data remains confidential. 
Any written materials or results will be written to ensure 
participant data remains confidential.
Qualitative research
The aim of the qualitative research will be to explore the 
participants’ experience of (1) the breathlessness reha-
bilitation programme (2) the COHERE trial and (3) any 
barriers or facilitators to participating and completing 
breathlessness rehabilitation. Participants who decline 
the trial are invited to a refusal interview, either face to 
face or over the telephone, providing consent is given. 
The qualitative data may provide information regarding 
the feasibility and scalability of the trial, reducing future 
recruitment or retention issues. On completion of the 
trial, research participants will be invited to a voluntary 
focus group or interview.
Focus groups and/or interviews will be conducted with 
healthcare professionals that have been actively involved 
in the COHERE trial, whereby the objective is to seek 
to understand the barriers, facilitators and experiences 
on the delivery and implementation of the breathless-
ness rehabilitation programme and the scalability of the 
COHERE trial in the future.
Qualitative data analysis
The qualitative data will be recorded, transcribed and 
analysed using thematic analysis. Thematic analysis allows 
emerging, recurrent themes or patterns to be identified 
from the data.44 All interviews and focus groups will be 
audio recorded with participant’s consent and tran-
scribed verbatim. Emerging themes will be identified 
throughout the trial, meaning the interview schedule and 
coding schedule are modified to follow new leads until 
new themes no longer emerge. In line with thematic 
analysis, there is no prespecified sample size; recruitment 
continues until no new themes emerge.
EthICs And dIssEMInAtIon
Findings from this feasibility trial will inform the design 
of future trials, largely the primary outcome measure and 
trial protocol. Furthermore, the findings will be shared 
locally with secondary care interface groups such as 
service managers. Some trial findings may be shared with 
national and international visitors who come to share our 
practice and a summary of the trial results will also be 
provided to participants. It is anticipated that the results 
from this feasibility trial will be presented at appropriate 
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national, international and regional conferences, local 
trial days and through peer-reviewed journals.
The trial is sponsored by UHL (trial number 
105410). Guidelines will be followed when protocol 
amendments are needed.
Protocol amendments
Any modifications to the protocol will be approved by 
Leicester South Research Ethics Committee prior to 
implementation and notified to the health authorities in 
accordance with local regulations.
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